Dr. Marcella is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
277 George St
New Brunswick, NJ 08901Phone+1 732-235-6700
Education & Training
Bridgeport Hospital/Yale UniversityResidency, Pediatrics, 1984 - 1987
Albany Medical CenterInternship, Internal Medicine, 1983 - 1984
New York University School of MedicineClass of 1983
Certifications & Licensure
NJ State Medical License 1995 - 2025
PA State Medical License 1987 - 1996- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Bone Mineral Density and Cancer Recurrence in Patients With Early Stage Prostate Cancer Start of enrollment: 2003 Jun 01
Publications & Presentations
PubMed
- 31 citationsAssociations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (20...Niyati Parekh, Yong Lin, Stephen Marcella, Ashima K. Kant, Grace L. Lu-Yao
Cancer Epidemiology, Biomarkers & Prevention. 2008-09-01 - 148 citationsRacial differences in colorectal cancer mortality. The importance of stage and socioeconomic status.Stephen Marcella, Jane E. Miller
Journal of Clinical Epidemiology. 2001-04-01 - 6 citationsCost effectiveness analysis of the New Jersey rapid testing algorithm for HIV testing in publicly funded testing sites.Kendall Stevinson, Eugene G. Martin, Stephen Marcella, Sindy M. Paul
Journal of Clinical Virology. 2011-12-01
Journal Articles
- Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab with Antibacterial Drug Treatment for Clostridium Difficile InfectionStephen Marcella, Yoav Golan, Clinical Infectious Diseases
Press Mentions
Novel Siderophore Cephalosporin Nets Promising Results in Tough-to-Treat CRABOctober 23rd, 2022- Shionogi to Present in Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETCROJA® (Cefiderocol) Against Gram-Negative PathogensSeptember 29th, 2021
Significant Costs Linked to Hospital-Acquired C. DifficileJuly 29th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
